A phase II study of neoadjuvant chemotherapy followed by organ preservation in patients with muscle-invasive bladder cancer
暂无分享,去创建一个
Santosh Kumar | B. Yadav | R. Kapoor | A. Lal | Narendra Kumar | P. Gupta | R. Mavuduru | C. Dracham | A. Elangovan
[1] Prashant Mathur,et al. Cancer Statistics, 2020: Report From National Cancer Registry Programme, India , 2020, JCO global oncology.
[2] R. Bristow,et al. Neoadjuvant Chemotherapy Before Bladder‐Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle‐Invasive Bladder Cancer , 2019, Clinical genitourinary cancer.
[3] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[4] Wei-Ting Hwang,et al. Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy: A Randomized Phase 2 Trial , 2017, JAMA surgery.
[5] T. H. van der Kwast,et al. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] A. Niemierko,et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. , 2017, European urology.
[7] J. Donovan,et al. Clinical and patient‐reported outcomes of SPARE – a randomised feasibility study of selective bladder preservation versus radical cystectomy , 2017, BJU international.
[8] L. Eapen,et al. The Rationale for Post-Operative Radiation in Localized Bladder Cancer , 2017, Bladder cancer.
[9] Y. Lotan,et al. Bladder cancer , 2016, The Lancet.
[10] M. Milowsky,et al. Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] K. Gaston,et al. Chemoradiation for organ preservation in the treatment of muscle-invasive bladder cancer. , 2016, Urologic oncology.
[12] O. Sager,et al. Outcomes of Trimodality Approach in the Management of T2N0M0 Bladder Cancer , 2015, Tumori.
[13] K. Hoffman,et al. Prostate cancer survivorship care guideline: American Society of Clinical Oncology Clinical Practice Guideline endorsement. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] M. Ghoneim,et al. Gemcitabine and cisplatin as neoadjuvant chemotherapy for invasive transitional and squamous cell carcinoma of the bladder: effect on survival and bladder preservation. , 2014, Clinical genitourinary cancer.
[15] W. Meinhardt,et al. Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone , 2014, BJU international.
[16] C. Tangen,et al. Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710 , 2014, Cancer.
[17] R. Huddart,et al. Randomized Noninferiority Trial of Reduced High-Dose Volume Versus Standard Volume Radiation Therapy for Muscle-Invasive Bladder Cancer: Results of the BC2001 Trial (CRUK/01/004) , 2013, International Journal of Radiation Oncology, Biology, Physics.
[18] J. Jakubowicz,et al. Transurethral resection, neoadjuvant chemotherapy and accelerated hyperfractionated radiotherapy (concomitant boost), with or without concurrent cisplatin, for patients with invasive bladder cancer – clinical outcome , 2013, Contemporary oncology.
[19] N. Vogelzang,et al. Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer. , 2013, The Journal of urology.
[20] R. Wahlqvist,et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. , 2012, European urology.
[21] R. Hautmann,et al. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. , 2012, European urology.
[22] A. Niemierko,et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. , 2012, European urology.
[23] A. Roychoudhury,et al. Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder. , 2012, Urology.
[24] T. Wilt,et al. Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma , 2011, BJU international.
[25] M. Parmar,et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] L. Muren,et al. CT-guided intensity-modulated radiotherapy for bladder cancer: isocentre shifts, margins and their impact on target dose. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[27] J. Logue,et al. Radiation therapy for muscle-invasive bladder cancer: treatment planning and delivery. , 2005, Clinical oncology (Royal College of Radiologists (Great Britain)).
[28] C. Vale. Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient Data: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration , 2005 .
[29] R. Hautmann,et al. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. , 2005, The Journal of urology.
[30] H. Grossman,et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] A. Zietman,et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. , 2003, The Journal of urology.
[32] Nicholas J Vogelzang,et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.
[33] H. Sandler,et al. Overview of bladder cancer trials in the Radiation Therapy Oncology Group , 2003, Cancer.
[34] F. Burkhard,et al. Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] J. Dunst,et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] I. Bodrogi,et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] B. Donnelly,et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of radiation therapy oncology group 89-03. , 1998, The Journal of urology.
[38] S. Johansson,et al. Long-term followup of a bladder carcinoma cohort: questionable value of radical radiotherapy. , 1997, The Journal of urology.
[39] N. Geller,et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. , 1985, The Journal of urology.
[40] J. Logue,et al. Radiation therapy for muscle-invasive bladder cancer: treatment planning and delivery in the 21st century. , 2005, Seminars in radiation oncology.